Compare American Electric Power Company Inc (AEP) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Electric Power Company Inc vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? American Electric Power Company Inc trades at $124.15 (market cap $67.28B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $357.58 (market cap $9.43B). The key difference: American Electric Power Company Inc is far larger — about 7.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and American Electric Power Company Inc pays a 3.07% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| AEP | BIO | |
|---|---|---|
Market Cap | $67.28B | $9.43B |
Sector | Utilities | Health |
52-Week High | $138.69 | $356.25 |
52-Week Low | $106.44 | $241.71 |
Enterprise Value | $120.17B | $9.18B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Electric Power (AEP) trades at $123.89, up 0.85% today, with a bearish technical signal but strong analyst support. Recent Q2 2026 earnings missed estimates at $1.36 EPS versus $1.48 expected, though revenue grew 7% year-over-year. The company raised full-year 2026 operating EPS guidance to $6.25–$6.55, citing robust demand from data centers and a $78 billion capital plan. Valuation metrics include a P/E of 21.42 and P/B of 2.1, with a consensus price target of $140.89 implying 14% upside.
AEP's outlook is supported by contracted load growth and infrastructure investments, but risks include execution of its capital plan and interest expense pressures. The stock offers a dividend yield with an upcoming $0.95 payment. Analyst consensus is strongly bullish with 61% buy ratings, though technical indicators suggest near-term caution. Long-term growth targets of 7–9% annually provide a solid foundation for patient investors.
Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.
The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
